SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Portfolio Pulse from
SELLAS Life Sciences announced positive results from its Phase 2a trial of SLS009 in combination with Zanubrutinib for treating DLBCL. The combination achieved a 67% overall response rate, significantly higher than Zanubrutinib alone, and an 83% disease control rate in non-GCB DLBCL patients.
February 20, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences' Phase 2a trial of SLS009 with Zanubrutinib shows promising results in DLBCL, potentially boosting investor confidence and stock price.
The trial results indicate a significant improvement in treatment efficacy, which is likely to enhance investor sentiment and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100